Founded in 2000, Bionostra - - in collaboration with members of the Consejo Superior de Investigaciones Cientficas (CSIC) which is the Spanish High Council of Scientific Research - - has developed a new technology based on virus-like-particles to provide a new generation of vaccines for human and animal health. These novel technology, will offer researchers at Mount Sinai School of Medicine a great jumping off point in the creation of the vaccine.
"We are enthusiastic with this promising collaboration between Bionostra and the Mount Sinai School of Medicine which is renowned for its prestigious scientific research," said Juan Carlos del Castillo Tamayo, CEO of Bionostra. "This is the first step for a revolutionary new generation of vaccines against the influenza virus."
Contact: Lucia Lee
The Mount Sinai Hospital / Mount Sinai School of Medicine